Oruka Therapeutics, Inc.
Stock Chart, Company Information, and Scan Results
Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.
Oruka Therapeutics, Inc. Company Information, Fundamentals, and Technical Indicators
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Oruka Therapeutics, Inc. In Our Stock Scanner
As of Sep 30, 2025
Join Our Free Email List
Get emails from us about ways to potentially make money in the stock market.